Investment Thesis
Alaunos Therapeutics is a clinical-stage pharmaceutical company with virtually no revenue ($5K), operating losses of $4.2M, and negative free cash flow of $3.0M—indicating a burn rate that will exhaust the $1.4M cash position in under 6 months. The company faces existential risk without immediate capital infusion or major commercial breakthrough, making it unsuitable for conservative investors.
Strengths
- Zero long-term debt eliminates leverage and interest burden
- Current ratio of 2.45x provides short-term liquidity buffer
- Cash position of $1.4M offers near-term operational runway
Risks
- Annual cash burn of ~$2.9-3.0M against $1.4M cash reserves creates <6 month runway
- Negligible revenue ($5K) with 50% YoY decline suggests no viable product commercialization
- Negative cash flow from operations unsustainable; company faces potential insolvency without financing
- Zero insider trading activity in past 90 days indicates lack of management confidence
- As development-stage pharma, pipeline success is critical but unproven and uncertain
Key Metrics to Watch
- Monthly cash burn rate and cash runway remaining
- Revenue growth from any pipeline advancement or product launch
- Operating cash flow trend and timing to positive operations
- Insider trading activity and management capital raises
Financial Metrics
Revenue
5.0K
Net Income
-4.2M
EPS (Diluted)
$-2.20
Free Cash Flow
-3.0M
Total Assets
3.0M
Cash
1.4M
Profitability Ratios
Gross Margin
N/A
Operating Margin
-84,500.0%
Net Margin
-83,520.0%
ROE
-194.0%
ROA
-140.8%
FCF Margin
-59,340.0%
Balance Sheet & Liquidity
Current Ratio
2.45x
Quick Ratio
2.45x
Debt/Equity
0.00x
Debt/Assets
27.4%
Interest Coverage
N/A
Long-term Debt
0.0
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-04-17T05:51:23.418675 |
Data as of: 2025-12-31 |
Powered by Claude AI